US Patent Issued to UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) on Feb. 3 for "Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis" (French Inventor)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,164, issued on Feb. 3, was assigned to UNIVERSITE DE STRASBOURG (Strasbourg, France) and INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris).

"Peptides for treatment and prevention of nonalcoholic fatty liver disease and fibrosis" was invented by Vincent Marion (Lipsheim, France).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially live...